Breaking News Coverage
for Alliqua, Inc. (OTCQB:ALQA) - October 21,
2013 |
- Last Trade: $
- Change:
- Open: $
- High: $
- Low: $
- Volume:
Company Snapshot |
Alliqua, Inc.
850 Third Avenue
Suite 1801
New York, NY 10022http://alliqua.com/
Officers:
David Johnson, CEO
Steven Berger, CFO
Tel: (646)218-1450
Email: info@alliqua.com
Sector: Biomedical/Healthcare
Ticker Symbol: ALQA
Exchange: OTCQB
Shares Outstanding: 273,924,657
52 Week Low: $0.03
52 Week High: $0.104
|
ALQA SMS Text Alerts |
Never miss news alerts from
ALQA - Text PRESS to 545454 for
Free News Alerts |
Alliqua Signs
Distribution Agreement for SilverSeal® and Hydress® Wound Dressings
U.S. Health Care Services Company to
Distribute SilverSeal and Hydress Dressings to
Alternate Site Market in All 50 States
LANGHORNE, PA – October 21, 2013 – Alliqua, Inc.
(OTCQB: ALQA) (“Alliqua” or “the Company”), has
signed a distribution agreement with McKesson
Medical-Surgical, by which their U.S.
distribution network will stock and offer for
sale Alliqua’s SilverSeal® and Hydress® wound
dressings to healthcare customers nationwide.
Get
News Alerts &
Stock Updates for Alliqua, Inc. delivered
directly to your Mobile Phone. Text
PRESS to 545454 (News
alerts are free; however standard message & data
rates may apply. Check with your carrier for
more details.)
David
Johnson, Chief Executive Officer of Alliqua,
said, “This encompasses expanding our
distribution network within the U.S. for our
SilverSeal® and Hydress® wound dressings.
McKesson Medical-Surgical is one of the most
well-known and respected health care
distributors in the U.S. market. The expansion
in distribution made possible by this agreement
will assist customers with easy access to these
products across the continuum of alternate site
health care. ”
Brad C. Barton, Chief Operating Officer of
Alliqua, stated, “Signing an agreement with
McKesson Medical-Surgical is very exciting to
our customer base. Whether in home care, long
term care or elsewhere in the alternate site
market, customers can access our products from a
source widely familiar to those in the position
of purchasing health care supplies.
Alliqua’s SilverSeal is a flexible, sterile
hydrogel dressing that incorporates the
antimicrobial properties of silver. It is
designed for use on partial and full-thickness
dermal ulcers, leg ulcers, superficial wounds,
abrasions, first and second degree burns, donor
sites and over debrided and grafted partial
thickness wounds.
Alliqua’s Hydress is a cross-linked
polymer-based gel that is able to provide and
maintain a moist wound environment. There are
several benefits associated with increased
moisture content, including the cleansing and
autolytic debriding of necrotic tissue.
Other terms of the agreement were not disclosed.
About McKesson
McKesson Medical-Surgical’s parent, McKesson
Corporation, currently ranked 14th on the
FORTUNE 500 list, is a healthcare services and
information technology company dedicated to
making the business of healthcare run better.
McKesson Medical-Surgical works with payers,
hospitals, physician offices, pharmacies,
pharmaceutical companies and others across the
spectrum of care to build healthier
organizations that deliver better care to
patients in every setting. McKesson
Medical-Surgical helps its customers improve
their financial, operational, and clinical
performance with solutions that include
pharmaceutical and medical-surgical supply
management, healthcare information technology,
and business and clinical services. For more
information, visit www.mckesson.com..
About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a
biopharmaceutical company focused on the
development, manufacturing, and distribution of
proprietary transdermal wound care and drug
delivery technologies. Alliqua's technology
platform produces hydrogels, a 3-dimensional
cross-linked network of water soluble polymers
capable of numerous chemical configurations.
Alliqua currently markets its new line of 510(k)
FDA-approved hydrogel products for wound care
under the SilverSeal® brand. Alliqua's electron
beam production process, located at its 16,000
square foot GMP manufacturing facility in
Langhorne, PA, allows Alliqua to develop and
custom manufacture a wide variety of hydrogels.
Alliqua's hydrogels can be customized for
various transdermal applications to address
market opportunities in the treatment of wounds
as well as the delivery of numerous drugs or
other agents for pharmaceutical and cosmetic
industries. Additionally, Alliqua's drug
delivery platform, in combination with certain
active pharmaceutical ingredients, can provide
pharmaceutical companies with a transdermal
technology to enhance patient compliance and
potentially extend the patent life of valuable
drug franchises.
For additional information, please visit
http://www.alliqua.com. To receive future press
releases via email, please visit
http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release
regarding our ongoing research and development
and the results attained by us to-date have not
been evaluated by the Food and Drug
Administration.
Legal Notice Regarding
Forward-Looking Statements
This release contains forward-looking
statements. Forward-looking statements are
generally identifiable by the use of words like
"may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or
other variations on these words or comparable
terminology. The reader is cautioned not to put
undue reliance on these forward-looking
statements, as these statements are subject to
numerous factors and uncertainties outside of
the our control that can make such statements
untrue, including, but not limited to,
inadequate capital, adverse economic conditions,
intense competition, lack of meaningful research
results, entry of new competitors and products,
adverse federal, state and local government
regulation, termination of contracts or
agreements, technological obsolescence of our
products, technical problems with our research
and products, price increases for supplies and
components, inability to carry out research,
development and commercialization plans, loss or
retirement of key executives and research
scientists and other specific risks. We
currently have no commercial products intended
to diagnose, treat, prevent or cure any disease.
The statements contained in this press release
regarding our ongoing research and development
and the results attained by us to-date have not
been evaluated by the Food and Drug
Administration. There can be no assurance that
further research and development, and/or whether
clinical trial results, if any, will validate
and support the results of our preliminary
research and studies. Further, there can be no
assurance that the necessary regulatory
approvals will be obtained or that we will be
able to develop new products on the basis of our
technologies. In addition, other factors that
could cause actual results to differ materially
are discussed in our Annual Report on Form
10-K/A filed with the SEC on May 16, 2013, and
our most recent Form 10-Q filings with the SEC.
Investors and security holders are urged to read
these documents free of charge on the SEC's web
site at http://www.sec.gov. We undertake no
obligation to publicly update or revise our
forward-looking statements as a result of new
information, future events or otherwise.
SOURCE: ALLIQUA, INC
Recent News Events for Alliqua, Inc. - OTCQB:
ALQA |
Preclinical Results Show Alliqua's
Investigational Lidocaine Transdermal Patch
Compares Favorably to Lidoderm Patch
Pharmacokinetic Study Encourages
Additional Testing
LANGHORNE, Pennsylvania, October 16, 2013
/PRNewswire via COMTEX/ -- A preclinical study
commissioned by Alliqua, Inc. (OTCQB: ALQA)
("Alliqua" or "the Company") concluded that the
Company's investigational lidocaine transdermal
patch compares favorably to the Lidoderm(r)
(Lidocaine patch 5%) patch that is currently on
the market. The overall study results indicate
that Alliqua's patch is able to deliver in the
pig a slightly higher amount of lidocaine than
Lidoderm and to reach maximum delivery within a
comparable period. No skin irritation
occurred with either the Alliqua transdermal
patch or Lidoderm patch. The study concludes
that further development could result in Alliqua
creating a commercial lidocaine patch that could
be a generic version of the Lidoderm patch or
provide better drug delivery resulting in a 505
(b)(2) approval.
David Johnson, Chief Executive Officer of
Alliqua, said, "As we continue to expand our
suite of wound care products, building the value
proposition of our hydrogel technology for
topical and transdermal drug delivery remains
one of our major goals. The results of this
preclinical study serve as a significant
motivation for us to continue our efforts to
develop a core transdermal delivery technology
platform to deliver lidocaine and other
beneficial ingredients through the skin."
James Sapirstein, Chief Executive Officer of
Alliqua Biomedical, said, "The strong showing of
our transdermal patch compared to Lidoderm, the
leading product currently on the market,
illustrates the potential of our technology. We
are evaluating our strategic options to maximize
these findings."
The primary objective of the study was to
conduct a comparative pharmacokinetic (PK)
analysis of lidocaine in Alliqua's transdermal
patch compared to Lidoderm in the pig. The
non-GLP in vivo crossover study was designed to
evaluate the delivery of lidocaine over 24 hours
in Alliqua's patch and Lidoderm with regard to
feasible length of application.
The study found that Alliqua's patch offers a
higher peak plasma concentration (Cmax) of
lidocaine than Lidoderm (4.961.16 ng/mL versus
3.031.92 ng/mL) and higher mean total area under
the curve (AUCtotal) than the competing product
66.5 ng/mL-h versus 48.9 ng/mL-h)). The mean
period of peak concentration (Tmax) was 8.7
hours for Alliqua's patch versus 10.7 hours for
Lidoderm.
In addition, Alliqua's patch was easier and
cleaner to remove from the skin after
application, with minimal or no patch impression
(outline) remaining. The presence of adhesive in
Lidoderm seemed to have a "peel-off effect" on
the skin (similar to a band-aid); in contrast,
Alliqua patch hydrogel has self-adhering
characteristics and is easily removed from the
skin at the end of a patch application without
residual skin markings.
Alliqua Provides Update on Media Coverage of
its Advanced Wound Care Portfolio and Corporate
Developments
LANGHORNE, Pennsylvania, October 7, 2013
/PRNewswire via COMTEX/ -- Alliqua, Inc.
provided an update on a series of independent
news stories highlighting the Company's wound
care portfolio and corporate developments. The
links below provide direct access to each
complete article.
Reports on Alliqua's corporate developments,
including its transformation into a wound care
products and technology company from a wound
care contract manufacturer, its growth strategy,
and recent strengthening of its management team,
were carried in the Philadelphia Business
Journal and Medical Device Daily. Separate
reports of Alliqua's SilverSeal� hydrogel wound
care dressing and its unique characteristics
were featured in Manufacturing Chemist Pharma,
WOUNDS and Qmed.com.
Links to the articles follow:
"Reinventing the Bandage with Hydrogels," on
Qmed.com:
http://www.qmed.com/mpmn/medtechpulse/reinventing-bandage-hydrogels
"Biopharm company gets new home, new focus," in
Philadelphia Business Journal:
http://www.bizjournals.com/philadelphia/blog/health-care/2013/09/biopharm-company-gets-new-home-new.html?page=all
"Lidocaine hydrogel patches will be developed to
treat localised acute pain," in the September
issue of Manufacturing Chemist:
http://www.manufacturingchemist.com/news/article_page/Lidocaine_hydrogel_patches_will_be_developed_to_treat_localised_acute_pain/91318
"Alliqua's SilverSeal Dressing Shown to Improve
Surgical Wound Outcomes in Clinical Study," on
the WOUNDS magazine website:
http://www.woundsresearch.com/news/alliquas-silverseal-dressing-shown-improve-surgical-wound-outcomes-clinical-study
David Johnson, CEO of Alliqua, said, "As our
company continues to meets its strategic growth
objectives, we are pleased to receive
recognition in the media for our achievements,
both in terms of our portfolio of wound care
products and our corporate developments,
including Alliqua's strong management team."
Alliqua Signs Long-Term Distribution
Agreement with sorbion for Hydroactive Wound
Product Line with Hydration Response Technology
LANGHORNE, Pennsylvania, September 23, 2013
/PRNewswire via COMTEX/ -- Partnership to Be
Officially Launched at SAWC in Las Vegas in
September
Adds to Alliqua's Suite of Advanced Wound Care
Solutions
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the
Company"), a biomedical company offering a suite
of wound care solutions and drug delivery
technologies, has signed a long-term agreement
with sorbion GmbH & Co. KG ("sorbion") to
distribute the sorbion sachet S, sorbion sana
and new products with hydrokinetic fibers as
primary dressings. sorbion hydroactive wound
care products will be distributed by Alliqua
throughout all of the Americas. The new
partnership will be officially launched at the
Fall 2013 Symposium on Advanced Wound Care
("SAWC"), to be held September 26-29 in Las
Vegas.
The sorbion sachet S and sorbion sana brands
have been market leaders in the MMP (matrix
metalloproteinase) modulator wound dressing
category in Germany and the U.K. for the past
several years and were initially introduced into
the U.S. marketplace three years ago. These
dressings are FDA-cleared and are reimbursable.
Intended for wound bed preparation, sorbion
sachet S is indicated as a primary dressing for
moderately to highly exudating wounds such as
surgical wounds, venous leg ulcers and diabetic
ulcers. It offers enhanced performance for the
removal of slough, and toxins, locking in
bacteria and reducing odor. sorbion sachet S's
hydration response technology combines
mechanically modified cellulose fibers with
gelling agents; the close interaction of the two
components allows for active regulation of the
wound climate.
Another
form of wound treatment is possible with sorbion
sana, which is indicated as a primary dressing.
It maintains a wound climate which supports
healing and thus supports granulation by
protecting tissue and offers a reduction of pain
during dressing changes. sorbion sana consists
of an absorbent core with hydration response
technology and a three-dimensional outer cover
made of polyethylene. Selected materials and an
optimized manufacturing process allow the
avoidance of glues and adhesives, making the
sorbion dressings less likely to cause an
allergic reaction.
Olaf Ohm, Sales & Marketing Director, Global
Operations of sorbion, said, "We are confident
that Alliqua is the ideal partner to expand the
distribution of the sorbion family of wound care
products across the Americas. Alliqua's team has
extensive wound care experience. sorbion's
products, when taken together with Alliqua's
SilverSeal� and Hydress� products, comprise an
ideal portfolio of wound care dressings from
which healthcare providers can choose to meet
the best needs of the patient."
Michael Stonner, Managing Director of sorbion,
said, "Alliqua's success in conveying the
specific benefits of its own wound care products
will serve us well as our international partner.
As Alliqua begins its distribution of sorbion
sachet S, sorbion sana, and new products with
hydrokinetic fibers in the Americas, we expect
the products' sales and reputation to grow at an
impressive rate."
David Johnson, Chief Executive Officer of
Alliqua, said, "This agreement is one example of
how Alliqua is fulfulling its vision to build a
suite of technological solutions that will allow
wound care practitioners to solve the challenges
that are presented to them in both chronic and
acute wounds. sorbion's products expand our
suite of wound dressings and together, these
products offer a broad range of solutions for
practitioners tasked with treating various wound
types and conditions providing a favorable wound
environment for healing. Overall, we expect the
clinical effectiveness of these products will
contribute to their role as very cost-effective
solutions for wound care specialists around the
globe."
About sorbion GmbH & Co. KG
sorbion GmbH & Co. KG is an owner-operated
company based in Senden (M�nsterland region,
Westphalia, Germany) which specializes in the
development, production and sale of products for
modern wound treatment. Since its foundation in
2001 by the Riesinger family, sorbion has
established itself as an internationally
acknowledged provider of modern treatment
solutions. Research and development has always
been one of the company group's main focuses
and, with new products and technologies, it is
central to the company's growth. Today, sorbion
is represented by sales and partner companies in
14 countries. For more information, please visit
http://www.sorbion.com.
Alliqua Initiates Proof-of-Principle Study
of Transdermal Lidocaine Hydrogel Patch for Pain
Relief
LANGHORNE, Pennsylvania, July 23, 2013
/PRNewswire via COMTEX/ -- Alliqua, Inc. (OTCQB:
ALQA) ("Alliqua" or the "Company") today
announced the initiation of a preclinical
proof-of-principle study of an experimental
hydrogel patch containing lidocaine. Safety and
tolerability of Alliqua's lidocaine hydrogel
patches will be explored in an animal model.
Further, the pharmacokinetic profile will be
analyzed to determine the amount of systemic
absorption and local lidocaine concentration in
the skin immediately beneath the patch.
"The ease of use, stability and compatibility
with active ingredients make our hydrogels well
suited for the transdermal delivery of a variety
of compounds, including pain medications like
lidocaine," commented James Sapirstein, chief
executive officer of Alliqua Biomedical. "Our
lidocaine patch development program is just the
first in our effort to build a portfolio of
products that leverage our hydrogel platform. We
believe success in this proof-of-principle study
for our lidocaine patch would increase the
likelihood of success with other compounds and
greatly enhances our efforts in this area.
Beyond lidocaine, the Alliqua Biomedical
division plans to explore transdermal delivery
of dermatological, oncology, antibiotic and
neurology products."
The Company plans to develop lidocaine hydrogel
patches for the treatment of localized acute
pain, including post-operative pain, back pain,
as well as pain associated with sports injuries
and arthritis. Alliqua expects results from this
preclinical proof-of-principle study later in
the third quarter.
"Lidocaine is an important therapeutic agent
with a strong potential market opportunity," Mr.
Sapirstein added. "Following successful
completion of this proof-of-principle study,
Alliqua intends to develop a clinical and
development path forward based on discussions
with the U.S. Food and Drug Administration as
well as scientific advisers and potential
partners."
Alliqua's SilverSeal Dressing Shown to
Improve Surgical Wound Outcomes in Clinical
Study
Study Results to be Presented at the
Annual Meeting of the American Orthopaedic Foot
& Ankle Society
LANGHORNE, Pennsylvania, July 18, 2013
/PRNewswire via COMTEX/ -- Alliqua, Inc. (OTCQB:
ALQA) ("Alliqua" or the "Company") today
announced the results from a post-marketing
study to assess surgical wound outcomes in
patients who have undergone foot and ankle
surgery. In this study, Alliqua's SilverSeal®
dressing was shown to have a lower incidence of
incision complications, including infection, and
a greater reduction in scar length compared to
standard petroleum-based dressing. Study results
are being presented at the annual meeting of the
American Orthopaedic Foot & Ankle Society, which
is being held in Hollywood, Florida July 17-20.
Stephen A. Brigido, DPM, director of the foot
and ankle fellowship at the Coordinated Health
Foot and Ankle Center and a primary investigator
in the study, stated, "The results from this
study are consistent with our preliminary
findings reported earlier this year and indicate
SilverSeal has potential to not only improve
post-surgical incision healing but to reduce
healthcare expenditures related to incision
complications."
"The reduction in post-surgical incision
complications and scarring shown in this study
is a meaningful benefit for patients as well as
for surgical centers and hospitals. We believe
this study demonstrates that SilverSeal can be
an effective tool in reducing complications such
as infection, and will be useful in driving
further adoption," added Philip Forman,
Alliqua's EVP of clinical affairs.
In this study, patients who had undergone ankle
and foot (including forefoot, midfoot or
hindfoot) surgery were randomized to receive
either SilverSeal or a standard petroleum-based
dressing. Patients were monitored for three
months following surgery to assess degree of
scarring and the incidence of incision
complications such as superficial or deep
infections or wound rupture, along the surgical
suture. Of the nine incision complications
observed, eight occurred in patients using the
petroleum-based dressing and only one in those
using SilverSeal (p=0.03). Length of
post-surgical scarring was also reduced to a
greater extent in patients using SilverSeal
compared to those with a standard
petroleum-based dressing.
These results are summarized in a poster titled
"Utilization of Silver Hydrogel Sheet Dressing
on Post-Surgical Incisions: A Pilot Study in
Foot & Ankle Surgery" that is currently being
presented at the American Orthopaedic Foot &
Ankle Society annual meeting.
Alliqua Raises $3 Million in 2nd Quarter of
2013, Led by Members of Management and its Board
of Directors
Equity Financings will Support Product and
Business Development Initiatives
NEW YORK, July 8, 2013 /PRNewswire via
COMTEX/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua"
or the "Company") today announced that it has
successfully met its financing goals, raising $3
million through the sale of common stock and
warrants over the past 3 months. A group of
accredited investors purchased the equity at
$0.081 per share, coupled with a warrant to
purchase an additional share of common stock at
$0.097 per share.
The first $1 million investment, as previously
disclosed by the Company, took place between
April and May of 2013. The remaining $2 million
was raised on June 28, 2013 and was led by group
of Alliqua's management and board of directors,
including Jerome Zeldis, Dave Johnson, David
Stefansky, Joseph Leone and Kenneth Pearsen. Dr.
Zeldis, who serves as the Chairman of the Board
of Alliqua, is the current chief medical officer
of Celgene Corporation. Mr. Johnson, who serves
as Alliqua's CEO, was previously the CEO of
Convatec. Mr. Johnson assumed the role of CEO of
Alliqua in February 2013. Mr. Stefansky, who
serves as a board member, is a co-founder and
principal of Harborview Advisors, LLC. Summer
Street Research Partners acted as lead
investment banker to raise funds outside of
insider participation.
Proceeds from the capital raises will provide
additional working capital to support the
Company's ongoing expansion of its wound
dressing portfolio, which includes marketed
products SilverSeal®
and Hydress®
dressings. It will also be used to further the
development of Alliqua's transdermal drug
delivery platform, as well as other potential
business expansion opportunities. "We are
excited to have completed this important
financing to help us support our continued sales
growth, as well as the advancement of key wound
care products," commented David Johnson,
Alliqua's CEO. "Moreover, I believe that the
substantial financial commitment on the part of
the executives and board members who contributed
to this financing round is indicative of our
commitment to the success of Alliqua as well as
our belief in the vast commercial potential we
all believe exists in our technology. Together,
we will continue to work diligently to drive
sales growth, improve design and functionality
of our dressings, expand our product lines and
further our transdermal drug delivery platform."
About Alliqua, Inc. - OTCQB: ALQA |
Alliqua, Inc. (OTCBB: ALQA) is a wound
management and drug delivery company that
creates superior outcomes for patients,
providers, and partners through its platform
technology and proprietary products.
Its core businesses include advanced wound care,
transdermal drug delivery, and contract
manufacturing. ALQA leverages its proprietary
hydrogel technology platform to add value to its
own products and also those of our partners.
Moving
Alliqua Forward in 2013: Increasing Revenues and
Expanding the Product Portfolio
Alliqua's hydrogel technology – the same
technology that gave the company its marketed
surgical dressings, SilverSeal® and HyDress® –
is the backbone of the company and represents an
enormous opportunity for growth in many ways. In
2013 ALQA intends to roll out a strategy to
leverage this technology platform.
First, ALQA is in the process of hiring a select
group of senior, proven, sales and marketing
managers who, together with its existing talent,
will strive to increase revenues from the
company's marketed products: Together, it
intends to:
•open up new distribution channels
•drive demand in our current channels including
the VA
•leverage the strong clinical data
Through these and the existing educational and
marketing efforts that are already underway,
Alliqua expects to see SilverSeal® and HyDress®
revenues start to increase in the Q2-Q4
timeframe.
Second, the company plans to utilize business
development opportunities to expand its product
offerings. Namely, ALQA intends to:
•focus on in-licensing marketed transdermal
products to fulfill its vision around leveraging
the hydrogel in transdermal drug delivery use.
Initially, the company intends to focus on wound
healing associated with pain, dermatology,
infection and cancer
•expand ALQA's portfolio beyond products with
potential hydrogel application by endeavoring to
in-license or acquire additional wound-care
products
This 2013 direction is intended to provide some
early wins, while building for sustained growth
in the future.
Wound Management
In the area of advanced wound care, ALQA
manufactures and market a line of proprietary
advanced wound dressings that include:
- SilverSeal®: A flexible, sterile,
non-adherent hydrogel dressing that
incorporates the antimicrobial properties of
metallic silver coated fiber.
- Hydress®: A flexible, sterile,
non-adherent hydrogel dressing that can
absorb two-times its weight in exudate.
ALQA is in the process of expanding its
advanced wound care portfolio to better meet the
needs of clinicians and the patients they serve.
This suite of differentiated advanced wound care
products will enhance their ability to
effectively and efficiently manage a variety of
wound indications and wound conditions
throughout the healthcare continuum.
Transdermal Drug Delivery
In the area of transdermal drug delivery, ALQA's
hydrogel technology can be used to deliver
therapeutic compounds through the skin. Key
advantages of our delivery platform include
stability of form and composition, purity,
reproducibility, and compatibility with various
active ingredients. Within certain patient
populations, transdermal drug delivery has
multiple advantages over oral drug delivery or
injections. Alliqua hydrogels provide a welcome
texture and flexibility for the patients; their
ease of administration is an added bonus. ALQA
intends to commercialize its drug delivery
platform in multiple therapeutic areas.
Contract Manufacturing
Alliqua contract manufacturing business unit
provides custom hydrogels to the OEM market. The
company develops and manufactures electron-beam
cross-linked sheet gels for customers that
include manufacturers of medical devices,
cosmeceuticals, and other commercial product
applications. ALQA's ability to meet the varying
specifications of its customers, while
maintaining tight tolerances and ensuring
delivery on-time and within budget, has made us
a leader in the electron beam cross-linked
hydrogel market.
FN Media Group LLC (FNMG) owns and operates
FinancialNewsMedia.com (FNM) is a third party
publishing provider which disseminates
electronic information through multiple online
media channels. FNMG's intended purposes are to
deliver market updates and news alerts issued
from private and publicly trading companies as
well as providing coverage and increased
awareness for companies that issue press to the
public via online newswires. FNMG and its
affiliated companies are a news dissemination
and financial marketing solutions provider and
are NOT a registered
broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to
sell or offer to buy any security. FNMG's market
updates, news alerts and corporate profiles are
NOT a solicitation or recommendation to buy,
sell or hold securities. An offer to buy or sell
can be made only with accompanying disclosure
documents from the company offering or selling
securities and only in the states and provinces
for which they are approved. The material in
this release is intended to be strictly
informational and is NEVER to be construed or
interpreted as research material. All readers
are strongly urged to perform research and due
diligence on their own and consult a licensed
financial professional before considering any
level of investing in stocks. The companies that
are discussed in this release may or may not
have approved the statements made in this
release. Information in this release is derived
from a variety of sources that may or may not
include the referenced company's publicly
disseminated information. The accuracy or
completeness of the information is not warranted
and is only as reliable as the sources from
which it was obtained. While this information is
believed to be reliable, such reliability cannot
be guaranteed. FNMG disclaims any and all
liability as to the completeness or accuracy of
the information contained and any omissions of
material fact in this release. This release may
contain technical inaccuracies or typographical
errors. It is strongly recommended that any
purchase or sale decision be discussed with a
financial adviser, or a broker-dealer, or a
member of any financial regulatory bodies.
Investment in the securities of the companies
discussed in this release is highly speculative
and carries a high degree of risk. FNMG is not
liable for any investment decisions by its
readers or subscribers. Investors are cautioned
that they may lose all or a portion of their
investment when investing in stocks.
This release is not without bias, and is
considered a conflict of interest if
compensation has been received by FNMG for its
dissemination. To comply with Section 17(b) of
the Securities Act of 1933, FNMG shall always
disclose any compensation it has received, or
expects to receive in the future, for the
dissemination of the information found herein on
behalf of one or more of the companies mentioned
in this release. For current services performed
FNMG has been compensated one thousand two
hundred fifty dollars for coverage of this news
release by Alliqua, Inc. (ALQA). FNMG HOLDS NO
SHARES OF Alliqua, Inc. (OTCQB:ALQA)
This release contains "forward-looking
statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and
Section 21E the Securities Exchange Act of 1934,
as amended and such forward-looking statements
are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe
future expectations, plans, results, or
strategies and are generally preceded by words
such as "may", "future", "plan" or "planned",
"will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are
cautioned that such statements are subject to a
multitude of risks and uncertainties that could
cause future circumstances, events, or results
to differ materially from those projected in the
forward-looking statements, including the risks
that actual results may differ materially from
those projected in the forward-looking
statements as a result of various factors, and
other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings
made by such company with the Securities and
Exchange Commission. You should consider these
factors in evaluating the forward-looking
statements included herein, and not place undue
reliance on such statements. The forward-looking
statements in this release are made as of the
date hereof and FNMG undertakes no obligation to
update such statements.
|